Mechanisms of drug resistance in ovarian cancer
DOI:
https://doi.org/10.12775/JEHS.2021.11.09.045Keywords
platinum resistance, PARPi resistance, ovarian cancer, drug resistanceAbstract
Ovarian cancer is the fifth most common cancer affecting women and the most lethal cancer among the gynecological cancers. Because of the lack of specific symptoms and no special screening tools, it is recognised in an advanced stage. In addition, drug resistance in ovarian cancer is so frequent, that genes and cross-talks between some important pathways are still analysed. In this review, the major and recently identified molecular mechanisms of drug resistance, including platinum, taxane, bevacizumab and PARPi resistance mechanisms in ovarian cancer from relevant literature have been investigated.
References
Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev. 2008 Mar;11(3–4):301–21.
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3–14.
Rooth C. Ovarian cancer: risk factors, treatment and management. Br J Nurs Mark Allen Publ. 2013 Sep 12;22(17):S23-30.
Gilani MM, Behnamfar F, Zamani F, Zamani N. Frequency of different types of ovarian cancer in Vali-e-Asr Hospital (Tehran University of Medical Sciences) 2001-2003. Pak J Biol Sci PJBS. 2007 Sep 1;10(17):3026–8.
Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res. 2019 Jan 28;12(1):9.
Recommendation of the Polish Society of Oncological Gynaecology on the diagnosis and treatment of epithelial ovarian cancer | Basta | Oncology in Clinical Practice [Internet]. [cited 2021 Jul 30]. Available from: https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/44800/36018
Chowanadisai W, Messerli SM, Miller DH, Medina JE, Hamilton JW, Messerli MA, et al. Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors. PloS One. 2016;11(3):e0151089.
Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010 Jun 15;17(6):574–83.
Zhu Z, Mu Y, Qi C, Wang J, Xi G, Guo J, et al. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro. Int J Mol Med. 2015 Feb;35(2):340–8.
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007 Aug;7(8):573–84.
Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, et al. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2009 Jun 1;15(11):3770–80.
Xiao X, Melton DW, Gourley C. Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications. Gynecol Oncol. 2014 Feb;132(2):506–12.
Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003 Mar 15;63(6):1311–6.
Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008 Apr 15;68(8):2581–6.
Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008 Feb 28;451(7182):1116–20.
Sedláková I, Laco J, Caltová K, Červinka M, Tošner J, Řezáč A, et al. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2015 Feb;25(2):236–43.
Ziółkowska-Seta I, Madry R, Kraszewska E, Szymańska T, Timorek A, Rembiszewska A, et al. TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol. 2009 Jan;112(1):179–84.
Anonymous. Avastin [Internet]. European Medicines Agency. 2018 [cited 2021 Sep 19]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/avastin
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473–83.
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 Oct 23;371(17):1609–18.
Sini V, Cassano A, Corsi D, De Laurentiis M, Gamucci T, Mauri M, et al. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons. Tumori. 2016 Oct 13;102(5):472–80.
Tai C-J, Wang H, Wang C-K, Tai C-J, Huang M-T, Wu C-H, et al. Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. Clin Exp Med. 2017 May;17(2):141–50.
Small AC, Oh WK. Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther. 2012 Sep;12(9):1241–9.
Guerrouahen BS, Pasquier J, Kaoud NA, Maleki M, Beauchamp M-C, Yasmeen A, et al. Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer. Mol Cancer Ther. 2014 Dec;13(12):3123–36.
Grepin R, Guyot M, Jacquin M, Durivault J, Chamorey E, Sudaka A, et al. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene. 2012 Mar 29;31(13):1683–94.
Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010 Dec 15;70(24):10090–100.
van der Bilt ARM, van der Zee AGJ, de Vries EGE, de Jong S, Timmer-Bosscha H, ten Hoor KA, et al. Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance. Curr Pharm Des. 2012;18(25):3784–92.
Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, et al. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene. 2018 Feb 8;37(6):722–31.
Mao X-G, Wang C, Liu D-Y, Zhang X, Wang L, Yan M, et al. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma. Oncotarget. 2016 Jul 26;7(30):47808–20.
Bunting SF, Callén E, Wong N, Chen H-T, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010 Apr 16;141(2):243–54.
Lawlor D, Martin P, Busschots S, Thery J, O’Leary JJ, Hennessy BT, et al. PARP Inhibitors as P-glyoprotein Substrates. J Pharm Sci. 2014 Jun;103(6):1913–20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 © The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 560
Number of citations: 0
